A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer.

CONCLUSION: Irinotecan and etoposide demonstrated only modest clinical activity and poor tolerability in patients with MBC refractory to anthracycline, taxane, and capecitabine therapy. Further studies testing a lower dose and/or different schedule could be considered given ease of administration and responses seen. PMID: 31383812 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31383812?dopt=Abstract

Source: The Oncologist - August 4, 2019 Category: Cancer & Oncology Authors: Segar JM, Reed D, Stopeck A, Livingston RB, Chalasani P Tags: Oncologist Source Type: research